AGP Picks
View all

Pulmonary hypertension market seen reaching $2.18 billion by 2030

13 hours ago
Pulmonary hypertension market seen reaching $2.18 billion by 2030
By AI, Created 17:30 UTC, Nov 17, 2026, AGP -

The pulmonary hypertension market is projected to grow from $1.55 billion in 2026 to $2.18 billion by 2030, according to The Business Research Company. The report points to targeted therapies, earlier diagnosis and remote monitoring as key forces behind the expansion.

Why it matters: - Pulmonary hypertension is a progressive heart and lung disorder that can lead to right heart failure if untreated. - Faster diagnosis and more precise treatment options could change outcomes for patients with a condition that remains difficult to manage. - The market outlook signals continued investment in rare disease drugs, monitoring tools and combination therapies.

What happened: - The Business Research Company released its Pulmonary Hypertension Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the pulmonary hypertension market will rise from $1.42 billion in 2025 to $1.55 billion in 2026. - The report forecasts the market will reach $2.18 billion by 2030. - The report projects an 8.9% compound annual growth rate over the forecast period.

The details: - Market growth is tied to a rising number of pulmonary hypertension cases. - Greater awareness of pulmonary vascular diseases is supporting demand. - Wider availability of specialized therapies is adding to growth. - Improvements in diagnostic tools are expanding detection. - More use of combination treatment methods is helping drive adoption. - The report says future growth will be supported by a pipeline of novel therapies. - Wider use of early detection techniques is expected to accelerate diagnosis. - Personalized treatment strategies are becoming a bigger focus. - Remote patient monitoring technologies are gaining adoption. - Investment in rare disease drug development is increasing. - Emerging trends include targeted pulmonary vasodilator therapies, earlier and more accurate diagnoses, combination therapies, customized treatments based on disease origins, and long-term monitoring and risk assessment. - Pulmonary hypertension causes symptoms such as shortness of breath, fatigue, chest pain and reduced exercise capacity. - The condition affects the arteries carrying blood from the heart to the lungs. - The increased pressure raises the workload on the right side of the heart. - Untreated disease can progress to right heart failure. - The report says targeted therapies are one of the main growth drivers because they focus on specific biological pathways or molecular processes. - Biomarker-based diagnostics are improving patient selection for those therapies. - In April 2025, the American Society of Gene & Cell Therapy reported that the number of gene therapies in Phase II trials rose to 306 in the first quarter of 2024.

Between the lines: - The market story is shifting from broad treatment approaches to precision medicine. - Better diagnostics appear to be pulling demand forward by identifying more patients earlier. - Remote monitoring and long-term risk assessment suggest care is moving beyond episodic treatment. - The report’s emphasis on rare disease development points to a wider industry push toward niche but high-value therapy areas. - North America held the largest market share in 2025, while Asia-Pacific is expected to be the fastest-growing region during the forecast period.

What's next: - The report expects continued expansion through 2030 as novel therapies move through the pipeline. - Early detection tools and biomarker-driven care are likely to become more central to treatment pathways. - The business outlook will be shaped by how quickly personalized therapies and monitoring technologies reach broader use. - More regional growth is expected outside North America, with Asia-Pacific leading the pace. - More information is available in the full report and a free sample.

The bottom line: - Pulmonary hypertension is becoming a bigger market as precision treatments, earlier diagnosis and monitoring tools reshape care.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Market Forecast Reports

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Market Forecast Reports

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.